Antimicrobial resistance has posed considerable health and economic burdens globally (approximately five million deaths annually), particularly among developing countries. The estimated annual treatment costs in the United States include US4. 6 billion. Vast antibiotic resistance among Gram-negative and Gram-positive bacterial species has spread from healthcare to the environment, community, and animals. These conditions have limited and sometimes failed the infection eradication choices and facilitated the distribution of drug-resistant organisms. The spread of drug-resistant bacterial infections is a huge human health concern, hence seeking novel antibacterial agents is crucial. This study used the nanoemulsions of Citrus aurantium and Artemisia annua essential oils (EOs) as natural antibacterial agents. GC–MS analysis showed that limonene (31. 4%) and artemisia ketone (26. 2%) were major components, respectively. After that, their nanoemulsion dosage forms with a mean droplet size of 181 ± 7 and 160 ± 5 and with zeta potential values 3. 1 ± 0. 8 and -4. 9 ± 0. 5 mV were prepared. Meanwhile, successful loading of the EOs in nanoemulsion was confirmed by ATR-FTIR analysis. A. annua nanoemulsion with 40% antioxidant effect was significantly more potent than C. aurantium nanoemulsion. Meanwhile, nanoemulsions' antibacterial and antibiofilm activity against clinical and standard strains, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumonia, were investigated. The best efficiency was related to the effect of C. aurantium nanoemulsion against S. aureus; MIC and MBC were 500 and > 2000 µg/mL. Besides, no biofilm was formed after treatment by both nanoemulsions. Therefore, C. aurantium and A. annua EO nanoemulsions may act as natural antioxidant and antibacterial agents in complementary medicine.
Osanloo et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: